Google's Veo 3.1 can turn separate images into a single video

ZDNET's key takeaways Google's new Veo 3.1 video model has landed.It can blend individual images into a unified video clip.Like its predecessor, it also creates videos with audio. Once upon a time, ...
Yahoo

Vertex’s quest for a breakthrough in Type 1 diabetes

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Vertex Pharmaceuticals’ CRISPR-based therapy made history as ...
The Motley Fool

What's Wrong With Vertex Pharmaceuticals Stock?

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...
Seeking Alpha

Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)

The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF ...
Benzinga.com

These Analysts Slash Their Forecasts On Vertex After Q2 Results

Vertex, Inc. (NASDAQ:VERX) reported weaker-than-expected sales for the second quarter and cut its FY25 sales guidance below estimates on Wednesday. Vertex reported quarterly earnings of 15 cents per ...
Investopedia

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
FiercePharma

Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...
Reuters

Vertex's trial failure, scrapped study cloud pain drug push; shares slump

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...
Wall Street Journal

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings

Vertex Pharmaceuticals’VRTX1.71%increase; green up pointing triangle stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into ...
Time

Vertex Pharmaceuticals

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.
Business Wire

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license ...
The Business Journals

Boston drugmaker Vertex slashes Providence workforce, shrinks real estate following trial failure

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Vertex Pharmaceuticals is laying ...